GlassScriptPhysician profile
Avtar S Parhar
NPI 1134186489
$16,785.58
in general payments reported to CMS, 2019-2025
49 companies · $1,868 in 2025
The $1,868 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,561 · 2020: $6,699 · 2021: $846 · 2022: $1,021 · 2023: $1,042 · 2024: $749 · 2025: $1,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,532 · Travel and Lodging: $953 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,531.59 |
| Travel and Lodging | $953.45 |
| Education | $173.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,742.66 | 2019-2023 | Ofev |
| Astrazeneca Pharmaceuticals LP | $2,154.92 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Noah Medical Corporation | $989.72 | 2025 | Galaxy |
| Philips North America LLC | $416.65 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Regeneron Healthcare Solutions, INC. | $243.21 | 2019-2023 | Dupixent |
| Insmed, INC. | $236.58 | 2024-2025 | Arikayce, Brinsupri |
| Pfizer INC. | $226.98 | 2019-2022 | |
| Abbvie INC. | $216.56 | 2021-2023 | |
| United Therapeutics Corporation | $185.12 | 2021-2025 | Tyvaso, Tyvaso |
| Electromed, INC. | $182.61 | 2019-2024 | Smartvest |
| Novo Nordisk INC | $163.94 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $150.21 | 2019-2025 | Nucala, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $141.95 | 2019-2022 | |
| Genzyme Corporation | $139.85 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $122.96 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avtar Parhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.